SCHEMBL772855

SCHEMBL772855

O=C(O)c1ccc2c(C3CCCCC3)c3n(c2n1)CCC(=O)c1cc(OCc2ccccc2)ccc1-3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.42
MAOA P21397 3/20 0.42
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
NFKB1 P19838 1/20 0.41
GRM5 P41594 1/20 0.41
RAB9A P51151 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GPR84 Q9NQS5 1/20 0.40
MCHR1 Q99705 1/20 0.39
HRH3 Q9Y5N1 2/20 0.39
P4HTM Q9NXG6 1/20 0.39
MCL1 Q07820 1/20 0.38
CYP2D6 P10635 1/20 0.38
P2RY14 Q15391 1/20 0.38
SPHK1 Q9NYA1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772156 0.93 PPARG (0.43) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL772345 0.87 MAOB (0.46) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL14572880 0.80 MAOB (0.43) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL771439 0.78 GAA (0.39) NPC1ALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL792770 0.73 MAOB (0.44) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL792413 0.73 MAOB (0.44) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL773170 0.72 KDM4E (0.36) ALDH1A1HPGD
SCHEMBL803848 0.70 MAOB (0.42) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL12428670 0.70 FFAR4 (0.34)
SCHEMBL772182 0.70 PRKCA (0.51) MAOBMAOANPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
EP-2206715-A1 Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor Japan Tobacco, Inc. (JP) 2010-07-14 EP disclosed
EP-1719773-B1 FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC (JP) 2009-04-15 EP disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed
EP-1719773-A1 FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR Japan Tobacco, Inc. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 MAOB 2789/4885MAOA 2994/4885NPC1 1131/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 MAOB 2789/4885MAOA 2994/4885NPC1 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.